新活素在重症病毒性心肌炎心力衰竭中的作用

目的 观察新活素在重症病毒性心肌炎心力衰竭中的疗效及安全性.方法 选取2010年1月至2013年12月在我科诊断的重症病毒性心肌炎患者27例,分为新活素组和对照组,新活素组在强心、利尿、扩血管基础上加用新活素治疗,观察两组患者脑利钠肽（BNP）、肌钙蛋白（cTnT）、肌酸激酶同工酶（CK-MB）、心脏彩超改变情况并比较两组的疗效.结果 新活素组能明显降低BNP [（203.1±39.8）vs.（1185.5±48.3） pg/ml]、cTnT [（13.5±9.8）vs.（24.8±13.2） μg/L]、CK-MB [（32.9±10.7）vs.（195.3 ±48.2） U/L],改善左室射血分数[（59.2±9.2）％vs.（38.1±8.8）％],并且疗效优于对照组（P＜0.05）,没有出现明显不良反应.结论 新活素对重症病毒性心肌炎心力衰竭是一个有效安全的治疗措施.

Effects of recombinant human brain natriuretic peptide on heart failure in acute severe viral myocarditis patients

Objective To investigate the effect and safety of recombinant human brain natriuretic peptide （rhBNP） on heart failure in acute severe viral myocarditis patients（ASVMC）.Methods 27 patients from Jan 2010 to Dec 2013 admitted to the Third Affiliated Hospital of Sun Yat-Sen University were divided into two group,rhBNP group 14 patients,control group 13 patients,rhBNP group received rhBNP on the treatment of cedilanid,diuresis,vascular dilation,BNP,cTnI,CK-MB and echocardiography were observed,therapeutic effect of two group were also observed.Results rhBNP decreased BNP [（203.1 ± 39.8） vs.（1185.5 ±48.3） pg/ml],cTnT [（13.5 ±9.8）vs.（24.8 ±13.2） μg/L],CK-MB[（32.9 ±10.7）vs.（195.3 ± 48.2） U/L],improved LVEF [（59.2 ± 9.2） % vs.（38.1 ± 8.8） %] significantly,P 〈 0.05.Furthermore,the therapeutic effect of rhBNP group were better than control group（P 〈 0.05）,and we didn＆#39; t observe obvious side effects in rhBNP group.Conclusion rhBNP is an effective and safe therapeutic measures for heart failure in ASVMC.